Sign in
CompletedPhase 3

A New Sildenafil Oral Film in Patients With Erectile Dysfunction

Key facts

Who runs it
IBSA Institut Biochimique SA
Where
Foley, Fort Lauderdale, Garden City, Huntsville, Knoxville, Las Vegas, Little Rock, Los Angeles, Miami, Murrieta, North Miami Beach, Palmetto Bay, Richmond, Rochester, Sugar Land, Sunrise, and Webster, United StatesSee the 18 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
488 people enrolled
Started
26 Jan 2024
Ended
9 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg
  • Placebo
Record updated
23 October 2025

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Heterosexual male subjects aged ≥18 years
  • Confirmed clinical diagnosis of ED for at least 6 months
  • Involved in a continuous sexual relationship with their partner for at least 3 months
  • Able and willing to provide voluntary written informed consent

Who cannot take part

  • Subjects taking a strong CYP3A4 inhibitor(s)
  • Patients must be stable on therapy with Alpha-blockers or Amlodipine at inclusion and already taking a PDE5 inhibitor without any safety concern prior to initiating the study (i.e., no history of significant side-effects with co-administration of PDE5 inhibitors)
  • Subjects known to abuse alcohol or drugs that could interfere with the patient's safety or study compliance
  • Currently suffering from any oromucosal condition or recent oral surgery that could interfere with the study drug
  • Any history of Peyronie's disease; or who have conditions which may predispose them to priapism
  • Any history or comorbidity of hypoactive sexual desire disorder, premature ejaculation or other ejaculatory disorders or radical prostatectomy
  • Any history of severe/uncontrolled diabetes or radical prostatectomy or spinal cord injury
  • Hypersensitivity to Sildenafil or to any of the excipients of the oral film, or idiosyncratic reactions to other PDE5 inhibitors
  • Any history of migraine
  • Any history of complete unresponsiveness to PDE5 inhibitor treatment or significant side-effects with PDE5 inhibitor
  • Subjects with or with history of severe vision impairment, temporary visual disturbances (blurred vision, increased light sensitivity and color change), retinitis pigmentosa, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) or any optic neuropathy
  • Patients ≥ 65 years with any degree of hepatic impairment or severe renal impairment or any significant pulmonary, gastrointestinal, hematological, endocrinal, metabolic or neurological disorder
  • Patients < 65 years with severe hepatic impairment
  • Any significant cardiovascular abnormality
  • Any presence of chronic indwelling urethral catheterization or penile anatomical abnormalities that would significantly impair EF
  • During the course of the study, subjects are not allowed to take any prescription, over-the-counter, herbal, or naturopathic products for "male enhancement" or the treatment of ED
  • During the course of the study, subjects are not allowed to take any form of nitric oxide donors such as organic nitrates or organic nitrites either regularly and/or intermittently, and guanylate cyclase (GC) stimulators
  • Subjects who are illiterate or are unable to understand how to use eDiary and complete the questionnaires

Where in United States

  • G & L Research LLCFoley, United States
  • Innovation Medical Group LLC (Endo Care of South Florida)Fort Lauderdale, United States
  • AccuMed Research AssociatesGarden City, United States
  • Medical Affiliated Research CenterHuntsville, United States
  • Alliance for Multispeciaty Research, LLCKnoxville, United States
  • Alliance for Multispecialty Research, LLCLas Vegas, United States
  • Arkansas Urology Research CenterLittle Rock, United States
  • Urology Group of Southern CaliforniaLos Angeles, United States
  • Clintex Research GroupMiami, United States
  • Coral Research ClinicMiami, United States
  • Tri Valley Urology Medical GroupMurrieta, United States
  • Harmony Clinical ResearchNorth Miami Beach, United States
  • Innovation Clinical Trials: Medical Reseach CenterPalmetto Bay, United States
  • Virginia UrologyRichmond, United States
  • Rochester Clinical Research, IncRochester, United States
  • Mt. Olympus Medical Research Group, LLCSugar Land, United States
  • Precision Clinical Research, LLCSunrise, United States
  • Tranquil Clinical and Research Consulting Services, LLCWebster, United States

About the trial

What the trial wants to find out

This is a Phase III, prospective, interventional, multi-center, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical study required by FDA to demonstrate the efficacy and safety of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg as compared to placebo in approximately 488 men clinically diagnosed with erectile dysfunction (ED).

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo oral film, on-demand use once per day, at maximum 60 films during a 12-week period

  • SildenafilTreatment being tested

    Sildenafil 25 mg, 50 mg, 75 mg or 100 mg oral film (flexible-dose), on-demand use once per day, at maximum 60 films during a 12-week period

    Treatment: Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Prospective, Randomized, Double-blind, Flexible-dose, Placebo-controlled, Parallel Group Clinical Trial of Sildenafil Oral Film 25 mg, 50 mg, 75 mg and 100 mg for the Treatment of Erectile Dysfunction (ED)
Record updated
23 October 2025